Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.92 USD
Change Today -1.43 / -3.73%
Volume 136.9K
ANIK On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 2:56 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

anika therapeutics inc (ANIK) Snapshot

Open
$38.32
Previous Close
$38.35
Day High
$39.12
Day Low
$36.90
52 Week High
06/9/14 - $51.40
52 Week Low
10/15/14 - $34.16
Market Cap
555.1M
Average Volume 10 Days
164.6K
EPS TTM
$2.48
Shares Outstanding
15.0M
EX-Date
--
P/E TM
14.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for ANIKA THERAPEUTICS INC (ANIK)

Related News

No related news articles were found.

anika therapeutics inc (ANIK) Related Businessweek News

No Related Businessweek News Found

anika therapeutics inc (ANIK) Details

Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company’s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company’s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise Hyalobarrier, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product for the prevention of spinal post-surgical adhesions; Merogel, a woven fleece nasal packin; and Merogel Injectable, a viscous hydrogel. The company’s ophthalmic products include STAARVISC-II, Optivisc, AnikaVisc, and NUVISC that are injectable HA products used as viscoelastic agents in ophthalmic surgical procedures, including cataract extraction and intraocular lens implantation. Its veterinary product comprise HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. markets its products through a network of distributors. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

105 Employees
Last Reported Date: 03/13/15
Founded in 1983

anika therapeutics inc (ANIK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $998.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $459.0K
Chief Operating Officer
Total Annual Compensation: --
Chief Technology & Strategy Officer
Total Annual Compensation: $43.4K
Compensation as of Fiscal Year 2014.

anika therapeutics inc (ANIK) Key Developments

Anika Therapeutics Announces Completion of Enrollment in Cingal 13-02 Study

Anika Therapeutics Inc. announced the completion of enrollment in the Cingal 13-02 study, an open-label, follow-on study to the Cingal 13-01 study, to evaluate the safety of a repeat injection of cross-linked sodium hyaluronate combined with triamcinolone hexacetonide (Cingal) intended to provide symptomatic relief of osteoarthritis (OA) of the knee. A total of 242 subjects, all of whom participated in the Cingal 13-01 study, were enrolled and re-treated with an additional Cingal injection. Study results will be available mid-year, and they will be used to support labeling for repeat injections with Cingal. Cingal combines the cross-linked hyaluronic acid formulation of Monovisc®, approved to provide long-term relief of the symptoms of OA, with an FDA-approved steroid to provide additional short-term pain relief. In the pivotal Cingal 13-01 study, 368 subjects were enrolled in a multicenter, randomized, double blind, saline-controlled study with an active comparator arm (Monovisc). The Cingal 13-01 study was conducted to investigate the safety and efficacy of Cingal in treating pain in patients with OA. The study results demonstrated that Cingal is statistically and clinically superior to saline with the data meeting the primary and all secondary endpoints. Adverse event rates were very low, evidencing the safety of the product. In the Cingal 13-01 study, Cingal met the primary endpoint by demonstrating superiority over saline for the change in WOMAC Pain Score over baseline levels through 12 weeks after treatment in the Intent to Treat (ITT) population (-40.2 mm vs. -31.0 mm, p=0.0099). The benefits proved long lasting as Cingal delivered a 72% improvement (-42.4 mm, p<0.01) in WOMAC Pain Score relative to baseline at 26 weeks after injection. Cingal also met all secondary endpoints relative to saline in the ITT analysis. Over 92.0% of Cingal subjects met the definition of OMERACT- OARSI Responders through 26 Weeks (p=0.01 vs. saline). Global Assessments (Patient and Evaluator) show the strong clinical benefit of Cingal through 26 weeks, with improvements over saline of 10.6 mm and 9.1 mm respectively (p<0.01). In addition to pain relief, endpoints measuring stiffness and physical function through 26 weeks support the superiority of Cingal compared with saline (p=0.01 and p=0.02, respectively). These study results were included in pre-marketing applications submitted in the United States and European Union, and they demonstrate that Anika’s single injection HA viscosupplementation product, Monovisc, provides long-term pain relief and that the addition of the steroid provides a short-term, statistically-significant improvement in pain reduction during the first three weeks following treatment.

Anika Therapeutics Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 09:30 AM

Anika Therapeutics Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 09:30 AM. Venue: MGM Grand Hotel, Las Vegas, Nevada, United States. Speakers: Charles H. Sherwood, Chief Executive Officer, President and Director.

Anika Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Full Year 2015

Anika Therapeutics Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company announced total revenue of $23,254,469 compared to $21,251,328 for the same period a year ago. Income from operations was $12,087,385 compared to $10,430,528 for the same period a year ago. Income before income taxes was $12,129,183 compared to $10,412,097 for the same period a year ago. Net income was $7,816,076 compared to $6,654,369 for the same period a year ago. Diluted net income per share was $0.51 compared to $0.44 for the same period a year ago. The increases in total revenue and product revenue versus the prior year periods were largely driven by higher domestic visco supplementation revenue. Operating income, net income and earnings per share were higher versus the prior year periods primarily due to increased milestone revenue. For the full year, the company announced total revenue of $105,594,839 compared to $75,081,154 for the same period a year ago. Income from operations was $61,446,884 compared to $32,606,717 for the same period a year ago. Income before income taxes was $61,505,021 compared to $32,479,531 for the same period a year ago. Net income was $38,319,479 compared to $20,574,521 for the same period a year ago. Diluted net income per share was $2.51 compared to $1.39 for the same period a year ago. Total revenue for 2014 increased by 41% from the prior year, exceeding $100 million for the first time in Anika's history, driven by strong milestone revenue related to the U.S. approval and launch of Monovisc. 2014 was also a record year for product revenue, which grew by $3.7 million, or 5% year-over-year, to $75.5 million. For 2015, the company expects solid growth in revenue, led by significant uptick in sales of Monovisc and growth in Orthovisc. Revenue growth, excluding the impact from the 2014 U.S. Monovisc milestone, is expected to be in the low double-digit range driven by the growth from orthobiologics franchise.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANIK:US $37.00 USD -1.35

ANIK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IRIDEX Corp $10.35 USD +0.33
STAAR Surgical Co $9.24 USD +0.10
View Industry Companies
 

Industry Analysis

ANIK

Industry Average

Valuation ANIK Industry Range
Price/Earnings 15.3x
Price/Sales 5.4x
Price/Book 3.2x
Price/Cash Flow 15.0x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANIKA THERAPEUTICS INC, please visit www.anikatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.